14th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices
In-Person Event
Mar 02, 2018
La Jolla, California, USA
OVERVIEW
14th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices are organized by Complete Conference Management (CCM) and will be held on Mar 02, 2018 at Estancia La Jolla Hotel & Spa, La Jolla, California, United States of America.
The target audience for this medical event is Cardiologists, Internists, Primary Care Physicians, Emergency Medicine Physicians, Clinical Laboratorians, Nursing Professionals and Allied Healthcare Professionals. This CME Conference has been approved for a maximum of 6.00 Credits.
Conference Description :
This annual event is designed to provide the latest clinical data, guidelines, and evidence related to the clinical application of novel biomarkers in cardiovascular conditions. Topics cover state of the art application of biomarkers in the following clinical categories:
• Current standards/guidelines and biomarkers in the prediction, diagnosis and management of patients.
• High sensitivity troponin testing and the evolution of this novel biomarker in acute myocardial infarction and other cardiovascular conditions.
• Clinical application of biomarkers as a tool in the evolution of precision therapeutics.
• Evidence-based biomarker data in the peer-reviewed literature in cardiovascular, endocrine, renal, pulmonary and related diseases.
• The application of biomarkers in therapeutic and device trials as qualification criteria, surrogate endpoints, etc.
Conference Objectives are :
At the conclusion of this activity, participants should be able to:
• Describe the current standards of care associated with the application of biomarkers in the care of patients with acute coronary syndrome (ACS) (hsTroponin), heart failure (natriuretic peptides and others), acute kidney injury (AKI) (cell cycle markers, ProEnkephalin, NGAL, etc.) as well as diabetes, pulmonary hypertension and related illness.
• Cite recent literature that provides an evidence-basis for the use of biomarkers for prediction, diagnosis, and management of disease.
• Discuss the emerging biomarker applications in cardiac disease based on recent breaking clinical studies and clinical trials.
• Review new data in ACS, heart failure, diabetes, AKI, and other categories and biomarker tools in the emerging era of precision medicine.
• Apply non-traditional biomarkers including heart rate, serum sodium concentration, and pulmonary artery pressure to guide and improve the treatment of patients with cardiovascular disease.
• Apply biomarkers to help optimize selection of patients for cardiac devices, assess for response to device therapy, and improve prognostication of patients with devices.
• Identify novel mobile technologies, applications, and devices that are impacting patient care and personalized medicine, and describe various ways they are being used.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Cardiologists, Internists, Primary Care Physicians, Emergency Medicine Physicians, Clinical Laboratorians, Nursing Professionals and Allied Healthcare Professionals. This CME Conference has been approved for a maximum of 6.00 Credits.
Conference Description :
This annual event is designed to provide the latest clinical data, guidelines, and evidence related to the clinical application of novel biomarkers in cardiovascular conditions. Topics cover state of the art application of biomarkers in the following clinical categories:
• Current standards/guidelines and biomarkers in the prediction, diagnosis and management of patients.
• High sensitivity troponin testing and the evolution of this novel biomarker in acute myocardial infarction and other cardiovascular conditions.
• Clinical application of biomarkers as a tool in the evolution of precision therapeutics.
• Evidence-based biomarker data in the peer-reviewed literature in cardiovascular, endocrine, renal, pulmonary and related diseases.
• The application of biomarkers in therapeutic and device trials as qualification criteria, surrogate endpoints, etc.
Conference Objectives are :
At the conclusion of this activity, participants should be able to:
• Describe the current standards of care associated with the application of biomarkers in the care of patients with acute coronary syndrome (ACS) (hsTroponin), heart failure (natriuretic peptides and others), acute kidney injury (AKI) (cell cycle markers, ProEnkephalin, NGAL, etc.) as well as diabetes, pulmonary hypertension and related illness.
• Cite recent literature that provides an evidence-basis for the use of biomarkers for prediction, diagnosis, and management of disease.
• Discuss the emerging biomarker applications in cardiac disease based on recent breaking clinical studies and clinical trials.
• Review new data in ACS, heart failure, diabetes, AKI, and other categories and biomarker tools in the emerging era of precision medicine.
• Apply non-traditional biomarkers including heart rate, serum sodium concentration, and pulmonary artery pressure to guide and improve the treatment of patients with cardiovascular disease.
• Apply biomarkers to help optimize selection of patients for cardiac devices, assess for response to device therapy, and improve prognostication of patients with devices.
• Identify novel mobile technologies, applications, and devices that are impacting patient care and personalized medicine, and describe various ways they are being used.
Additional details will be posted as soon as they are available.
KEY DATES
02 Mar, 2018
Event Start Date
02 Mar, 2018
Event End Date
SPECIALITIES
CardiologySUGGESTED HOTELS
CONFERENCE VENUE
Estancia La Jolla Hotel & SpaRELATED CONFERENCES & LIVE WEBINARS
Quick Links